



1636
EPW

PATENT
ATTORNEY DOCKET NO. 50026/031001

Certificate of Mailing: Date of Deposit: July 12, 2004

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Janet D'Annunzio-Ellis

Printed name of person mailing correspondence

Janet D'Annunzio-Ellis

Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Nakajima et al.

Art Unit: 1636

Serial No.: 09/980,420

Examiner: Not Yet Assigned

Filed: June 5, 2002

Customer No.: 21559

Title: A VECTOR FOR THE EXPRESSION OF TWO FOREIGN GENES

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449, all of which were cited in the European Search Report from a corresponding European patent application. A copy of the European Search Report is enclosed.

Copies of the following references are enclosed.

Barksdale and Baker, "The Human Immunodeficiency Virus Type 1 Rev Protein and the Rev-Responsive Element Counteract the Effect of an Inhibitory 5' Splice Site in a 3' Untranslated Region," *Mol. Cell. Biol.*, 15(6):2962-2971, 1995.

Brighty and Rosenberg, "A Cis-Acting Repressive Sequence that Overlaps the Rev-Responsive Element of Human Immunodeficiency Virus Type 1 Regulates Nuclear Retention of *env* mRNAs Independently of Known Splice Signals," *Proc.*

Natl. Acad. Sci. USA, 91(18):8314-8318, 1994.

Dougherty and Temin, "High Mutation Rate of a Spleen Necrosis Virus-Based Retrovirus Vector," *Mol. Cell. Biol.*, 168(3):4387-4395, 1986.

Korman et al., "Expression of Human Class II Major Histocompatibility Complex Antigens Using Retrovirus Vectors," *Proc. Natl. Acad. Sci. USA*, 84(8):2150-2154, 1987.

Naldini et al., "In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector," *Science*, 272(5259):263-267, 1996.

US 5,739,118 A

WO 99/15683 A1

Applicants note that AU 750110 B2, AU 9175698 A, AU 747609 B2, AU 9356298 A, CA 2303663 A1, CA 2304259 A1, CN 1279723 T, CN 1303442 T, EP 1017837 A1, EP 1017838 A2, GB 2344592 A, B, GB 2345063 A, B, JP 2001-517452 T, JP 2001-517453 T, NO 20001486 A, NO 20001487 A, NZ 503317 A, NZ 503318 A, and WO 99/15684 A2, are patent family members of WO 99/15683 A1, and that AU 709659 B2, AU 2236695 A, CA 2186913 A1, EP 0772437 A1, JP 9-511146 T, WO 95/26718 A1, and US 6,197,755 B1 are patent family members of US 5,739,118 A. Copies of these patent family members of WO 99/15683 A1 and US 5,739,118 A are not enclosed.

Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.

This statement is being filed before the receipt of a first Office Action on the


merits.

If there are any charges or any credits, please apply them to Deposit Account No.

03-2095.

Respectfully submitted,

Date: 12 July 2004




Jan N. Tittel, Ph.D.
Reg. No. 52,290

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045



Sheet 1 of 3

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Attorney Docket No. 50026/031001		
				Serial No. 09/980,420		
				Applicant Nakajima et al.		
				Filing Date June 5, 2002		
				Group 1636		
				IDS Filed JULY 12, 2004		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)						
(37 C.F.R. § 1.98(b))						
U.S. PATENTS						
Examiner's Initials	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)
	5,739,118 A	April 14, 1998	Carrano et al.			
	6,197,755 B1	March 6, 2001	Carrano et al.			
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
	AU 709659 B2	September 2, 1999	Australia			
	AU 747609 B2	May 16, 2002	Australia			
	AU 750110 B2	July 11, 2002	Australia			
	AU 9175698 A	April 12, 1999	Australia			
	AU 9356298 A	April 12, 1999	Australia			
	AU 2236695 A	October 23, 1995	Australia			
	CA 2186913 A1	October 12, 1995	Canada			
	CA 2303663 A1	April 1, 1999	Canada			
	CA 2304259 A1	April 1, 1999	Canada			
	CN 1279723 T	January 10, 2001	China			
	CN 1303442 T	July 11, 2001	China			
	EP 0772437 A1	May 14, 1997	EPO			
	EP 1017837 A1	July 12, 2000	EPO			
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)						
EXAMINER			DATE CONSIDERED			
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.						



SUBSTITUTE FORM 10-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	50026/031001
	Serial No.	09/980,420
	Applicant	Nakajima et al.
	Filing Date	June 5, 2002
	Group	1636
	IDS Filed	JULY 12, 2004

U.S. PATENTS

Examiner's Initials	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
	EP 1017838 A2	July 12, 2000	EPO			
	GB 2344592 A, B	June 14, 2000	United Kingdom			
	GB 2345063 A, B	June 28, 2000	United Kingdom			
	JP 9-511146 T	November 11, 1997	Japan			
	JP 2001-517452 T	October 9, 2001	Japan			
	JP 2001-517453 T	October 9, 2001	Japan			
	NO 20001486 A	May 25, 2000	Norway			
	NO 20001487 A	May 23, 2000	Norway			
	NZ 503317 A	May 31, 2002	New Zealand			
	NZ 503318 A	November 30, 2001	New Zealand			
	WO 95/26718 A1	October 12, 1995	WIPO			
	WO 99/15683 A1	April 1, 1999	WIPO			
	WO 99/15684 A2	April 1, 1999	WIPO			

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)

	Barksdale and Baker, "The Human Immunodeficiency Virus Type 1 Rev Protein and the Rev-Responsive Element Counteract the Effect of an Inhibitory 5' Splice Site in a 3' Untranslated Region," <i>Mol. Cell. Biol.</i> , 15(6):2962-2971, 1995.
	Brighty and Rosenberg, "A Cis-Acting Repressive Sequence that Overlaps the Rev-Responsive Element of Human Immunodeficiency Virus Type 1 Regulates Nuclear Retention of <i>env</i> mRNAs Independently of Known Splice Signals," <i>Proc. Natl. Acad. Sci. USA</i> , 91(18):8314-8318, 1994.
	Dougherty and Temin, "High Mutation Rate of a Spleen Necrosis Virus-Based Retrovirus Vector," <i>Mol. Cell. Biol.</i> , 168(3):4387-4395, 1986.

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.



Sheet 3 of 3

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Attorney Docket No. 50026/031001 Serial No. 09/980,420 Applicant Nakajima et al. Filing Date June 5, 2002 Group 1636 IDS Filed JULY 12, 2004		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)						
(37 C.F.R. § 1.98(b))						
U.S. PATENTS						
Examiner's Initials	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)						
	Korman et al., "Expression of Human Class II Major Histocompatibility Complex Antigens Using Retrovirus Vectors," <i>Proc. Natl. Acad. Sci. USA</i> , 84(8):2150-2154, 1987.					
	Naldini et al., "In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector," <i>Science</i> , 272(5259):263-267, 1996.					
EXAMINER				DATE CONSIDERED		
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.						